An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells

Molecular Medicine Reports

Volumn 8, Issue 5, 2013, Pages 1416-1424

  Fang, Lin ^a   Cheng, Qian ^a   Bai, Jin ^a   Qi, Ying Dong ^a   Liu, Jun Jie ^a   Li, Lian Tao ^a   Zheng, Jun Nian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Interleukin 24; Oncolytic adenovirus; Paclitaxel

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; FLUORESCEIN ISOTHIOCYANATE; INTERLEUKIN 24; LIPOCORTIN 5; MESSENGER RNA; ONCOLYTIC ADENOVIRUS; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CYTOTOXICITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FEMALE; HUMANS; INTERLEUKINS; ONCOLYTIC VIROTHERAPY; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 84885087698     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1680     Document Type: Article

References (45)

1. Krychman ML and Katz A: Breast cancer and sexuality: multi-modal treatment options. J Sex Med 9: 5-13, 2012.
2. Haas JS, Liang SY, Hassett MJ, Shiboski S, Elkin EB and Phillips KA: Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat 130: 619-626, 2011.
3. Choi JW, Lee JS, Kim SW and Yun CO: Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 64: 720-729, 2012.
4. Huang JH, Zhang SN, Choi KJ, et al: Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther 18: 264-274, 2010.
5. Hashimoto Y, Tazawa H, Teraishi F, et al: The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment. PLoS One 7: e39292, 2012.
6. Fang L, Pu YY, Hu XC, et al: Antiangiogenesis gene armed tumor-targeting adenovirus yields multiple antitumor activities in human HCC xenografts in nude mice. Hepatol Res 40: 216-228, 2010.
7. Cho WK, Seong YR, Lee YH, et al: Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 10: 938-949, 2004.
8. Ulasov IV, Zhu ZB, Tyler MA, et al: Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 18: 589-602, 2007.
9. Kim KI, Park JH, Lee YJ, et al: In vivo bioluminescent imaging of α-fetoprotein producing hepatocellular carcinoma in diethylnitrosamine- treated mouse using recombinant adenoviral vector. J Gene Med 14: 513-520, 2012.
10. Kwon OJ, Kim PH, Huyn S, Wu L, Kim M and Yun CO: A hypoxia- and α-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 16: 6071-6082, 2010.
11. Nakagawa T, Tanaka H, Shirakawa T, et al: Cyclooxygenase 2 promoter-based replication-selective adenoviral vector for hypopharyngeal cancer. Arch Otolaryngol Head Neck Surg 135: 282-286, 2009.
12. Bauerschmitz GJ, Guse K, Kanerva A, et al: Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 14: 164-174, 2006.
13. Ganesh S, Gonzalez-Edick M, Gibbons D, Waugh J, Van Roey M and Jooss K: Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice. Hum Gene Ther 20: 1201-1213, 2009.
14. Hoffmann D, Meyer B and Wildner O: Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J Gene Med 9: 764-778, 2007.
15. Wakayama M, Abei M, Kawashima R, et al: E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CA-deficient biliary cancers. Clin Cancer Res 13: 3043-3050, 2007.
16. Ries SJ, Brandts CH, Chung AS, et al: Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 6: 1128-1133, 2000.
17. Harada JN and Berk AJ: p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 73: 5333-5344, 1999.
18. Heise C, Hermiston T, Johnson L, et al: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6: 1134-1139, 2000.
19. Zhang ZL, Zou WG, Luo CX, et al: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 13: 481-489, 2003.
20. Tian H, Wang J, Zhang B, et al: MDA-7/IL-24 induces Bcl-2 denitrosylation and ubiquitin-degradation involved in cancer cell apoptosis. PLoS One 7: e37200, 2012.
21. Jiang G, Liu YQ, Wei ZP, Pei DS, Mao LJ and Zheng JN: Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazine against melanoma cells via induction of apoptosis. Cancer Lett 294: 220-228, 2010.
22. Halldén G: Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. J BUON 14 (Suppl 1): S61-S67, 2009.
23. Saito K, Shirasawa H, Isegawa N, Shiiba M, Uzawa K and Tanzawa H: Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses. Oral Oncol 45: 1021-1027, 2009.
24. Khuri FR, Nemunaitis J, Ganly I, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885, 2000.
25. Cherubini G, Kallin C, Mozetic A, et al: The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther 18: 1157-1165, 2011.
26. Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR and Halldén G: An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther 18: 734-743, 2011
27. Ingemarsdotter CK, Baird SK, Connell CM, Öberg D, Halldén G and McNeish IA: Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 29: 6051-6063, 2010.
28. Gao Y, Nankya I, Abraha A, et al: Calculating HIV-1 infectious titre using a virtual TCID(50) method. Methods Mol Biol 485: 27-35, 2009.
29. Walker RA, Hanby A, Pinder SE, Thomas J, Ellis IO; National Coordinating Committee for Breast Pathology Research Subgroup: Current issues in diagnostic breast pathology. J Clin Pathol 65: 771-785, 2012.
30. Wong HH, Lemoine NR and Wang Y: Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2: 78-106, 2010.
31. Cun B, Song X, Jia R, et al: Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block. Cancer Biol Ther 13: 77-84, 2012.
32. Abate-Daga D, Andreu N, Camacho-Sánchez J, et al: Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing. PLoS One 6: e26142, 2011.
33. Chu RL, Post DE, Khuri FR and Van Meir EG: Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 10: 5299-5312, 2004.
34. Menzin AW, King SA, Aikins JK, Mikuta JJ and Rubin SC: Taxol (paclitaxel) was approved by FDA for the treatment of patients with recurrent ovarian cancer. Gynecol Oncol 54: 103, 1994.
35. Flores ML, Castilla C, Ávila R, Ruiz-Borrego M, Sáez C and Japón MA: Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction. Breast Cancer Res Treat 133: 917-928, 2012.
36. Lu PH, Yu CC, Chiang PC, et al: Paclitaxel induces apoptosis through activation of nuclear protein kinase C-δ and subsequent activation of Golgi associated Cdk1 in human hormone refractory prostate cancer. J Urol 186: 2434-2441, 2011.
37. Le XF, Mao W, He G, et al: The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst 103: 1403-1422, 2011.
38. Heikaus S, Matuszek KS, Suschek CV, et al: Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L). J Cancer Res Clin Oncol 134: 689-695, 2008.32.
39. Abate-Daga D, Andreu N, Camacho-Sánchez J, et al: Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing. PLoS One 6: e26142, 2011.
40. Chu RL, Post DE, Khuri FR and Van Meir EG: Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 10: 5299-5312, 2004.
41. Menzin AW, King SA, Aikins JK, Mikuta JJ and Rubin SC: Taxol (paclitaxel) was approved by FDA for the treatment of patients with recurrent ovarian cancer. Gynecol Oncol 54: 103, 1994.
42. Flores ML, Castilla C, Ávila R, Ruiz-Borrego M, Sáez C and Japón MA: Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction. Breast Cancer Res Treat 133: 917-928, 2012.
43. Lu PH, Yu CC, Chiang PC, et al: Paclitaxel induces apoptosis through activation of nuclear protein kinase C-δ and subsequent activation of Golgi associated Cdk1 in human hormone refractory prostate cancer. J Urol 186: 2434-2441, 2011.
44. Le XF, Mao W, He G, et al: The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst 103: 1403-1422, 2011.
45. Heikaus S, Matuszek KS, Suschek CV, et al: Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L). J Cancer Res Clin Oncol 134: 689-695, 2008.